Drug repurposing for cancer therapy DOI Creative Commons
Ying Xia, Ming Sun, Hai Huang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: April 18, 2024

Abstract Cancer, a complex and multifactorial disease, presents significant challenge to global health. Despite advances in surgical, radiotherapeutic immunological approaches, which have improved cancer treatment outcomes, drug therapy continues serve as key therapeutic strategy. However, the clinical efficacy of is often constrained by resistance severe toxic side effects, thus there remains critical need develop novel therapeutics. One promising strategy that has received widespread attention recent years repurposing: identification new applications for existing, clinically approved drugs. Drug repurposing possesses several inherent advantages context since repurposed drugs are typically cost-effective, proven be safe, can significantly expedite development process due their already established safety profiles. In light this, present review offers comprehensive overview various methods employed repurposing, specifically focusing on treat cancer. We describe antitumor properties candidate drugs, discuss detail how they target both hallmarks tumor cells surrounding microenvironment. addition, we examine innovative integrating with nanotechnology enhance topical delivery. also emphasize role play when used part combination regimen. To conclude, outline challenges associated consider future prospects these transitioning into application.

Language: Английский

Dynamic EMT: a multi‐tool for tumor progression DOI Creative Commons
Simone Brabletz, Harald Schuhwerk, Thomas Brabletz

et al.

The EMBO Journal, Journal Year: 2021, Volume and Issue: 40(18)

Published: Aug. 30, 2021

Review30 August 2021Open Access Dynamic EMT: a multi-tool for tumor progression Simone Brabletz Corresponding Author [email protected] orcid.org/0000-0003-0936-1526 Department of Experimental Medicine 1, Nikolaus-Fiebiger Center Molecular Medicine, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany Search more papers by this author Harald Schuhwerk orcid.org/0000-0001-6971-3760 Thomas orcid.org/0000-0003-2983-9048 Marc P. Stemmler orcid.org/0000-0002-7866-3686 Information *,1, Schuhwerk1, Brabletz1 and *,1 1Department *Corresponding author. Tel: +49 9131 85 29101; E-mail: The EMBO Journal (2021)40:e108647https://doi.org/10.15252/embj.2021108647 This article is part the Cancer Reviews 2021 series. PDFDownload PDF text main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Abstract process epithelial–mesenchymal transition (EMT) fundamental embryonic morphogenesis. Cells undergoing it lose epithelial characteristics integrity, acquire mesenchymal features, become motile. In cancer, program hijacked confer essential changes in morphology motility that fuel invasion. addition, EMT increasingly understood orchestrate large variety complementary cancer such as cell stemness, tumorigenicity, resistance therapy adaptation microenvironment. review, we summarize recent findings related these various classical non-classical functions, introduce true tumorigenic multi-tool, involved many aspects cancer. We suggest therapeutic targeting will—if acknowledging complexities—be possibility concurrently interfere with on levels. Introduction Epithelial-to-mesenchymal describes transdifferentiation stationary cells mesenchymal, motile phenotype was initially observed early development (Hay, 1995). Here, contributes embryonal processes like gastrulation, neural crest formation, or heart (Thiery et al, 2009; Nieto 2016). also crucial physiological wound healing (Arnoux 2008) tissue homeostasis (Ahmed 2006). Importantly, pathological reactivation plays role diseases organ fibrosis metastasis (Fig 1A), which focus review. Figure 1. Classical functions (A) frequently occurs at invasive front tumors, destroys well-defined structures, allows migrate, invade tissue, intravasate blood lymphatic vessels. Tumor their way through body can travel single cells, clusters exhibiting partial headed leader cell. At secondary site, extravasate colonize distant organ, where MET outgrowth macrometastases. (B) induced mainly set transcription factors (EMT-TFs) ZEB1, ZEB2, SNAIL, SLUG TWIST differ protein structure, size, individual functions. All them are repressors E-cadherin activate markers Vimentin, Fibronectin N-cadherin. Epithelial displaying apical–basal polarity held together tight junctions, adherens desmosomes anchored underlying basement membrane hemidesmosomes. They express three different complexes junctional molecules maintain polarity. EMT, expression EMT-TFs leads inhibition major components structures concomitantly activates genes associated state. gain front–rear polarity, display actin stress fibers, capacities. Notably, very rarely switch completely phenotype, but fluently convert between intermediate states certain features keeping sets characteristics. Further, reversible process. Mesenchymal revert state MET. An important execution played microRNAs miR-200 mir-34 families regulated double-negative feedback loops ZEB1/2 respectively, serve reinforce either Download figure PowerPoint an extremely complex diverse disease not only varying entities, within same entity, subtypes, even subtypes. tumors spatial temporal heterogeneity be elicited, e.g., via occurrence consecutive mutations clonal evolution (McGranahan Swanton, 2017). However, plasticity, allowing continuous adaption ever-changing conditions, mediated genetically fixed, depending accumulating mutations, epigenetically orchestrated signals from microenvironment, rendering whole (by activating mesenchymal–epithelial transition; MET) highly dynamic (see overview Fig 2). 2. Overview summarizing multiple oncogenic course progression. allow invade, intra- sites, enables traits support initiation well metastatic colonization. Throughout progression, they help cope changing conditions metabolic reprogramming, enhanced survival altered DNA repair prevention death, immune evasion improved chemo- radiotherapy. supporting handle environmental extracellular from, CAFs microenvironment approaches. executed core EMT-activating including SNAIL (also SNAI1) SNAI2), basic helix–loop–helix TWIST1 (TWIST) TWIST2 zinc finger E-Box binding homeobox ZEB1 ZEB2. share ability repress encoding gene CDH1 motifs cognate promoter regions (Nieto 2016) shown (Batlle 2000; Cano 2000), (Yang 2004), (Eger 2005), ZEB2 (Comijn 2001). parallel, directly indirectly VIM (Vimentin), FN1 (Fibronectin), CDH2 (N-cadherin) 2016; Dongre Weinberg, 2019) 1B). shared, distinct EMT-TFs, patterns size structure (Stemmler 2019). Beyond "classical" traits, motility, capacities, widespread importance biology indicated additional pleiotropic (Brabletz 2018). have been stemness properties increase linking concept stem (CSCs). Additionally, repair, escape senescence apoptosis, resistance, resulting pro-survival providing advantage under types conditions. Altogether, non-redundant context-dependent dynamically (TME) permanently adapt (Puisieux 2014). Consequently, intervention EMT/plasticity will provide opportunity fight blow. all highlight clinical implications. Classical/core Migration invasion normal form protective sheets structural integrity. connection junction junction, desmosomes, junctions seal located apical constitute barrier solutes water. apical-basal function, has defined "asymmetry" tissues. Polarity complexes, Par, Crumbs, Scribble ensure proper organization versus basolateral domains (Huang 2012). Of note, some control regulate spindle orientation division mode (Martin-Belmonte Perez-Moreno, 2011) Elicited TME, activation toward malignancy, accompanied substantial cellular Cell–cell contacts deconstructed repression CDH1, cadherin (E-cadherin), constituent coding other molecules. As consequence disintegration direct transcriptional several members Crumbs lost (Aigner 2007; Moreno-Bueno 2008; Spaderna Lamouille 2014) coincides profound cytoskeletal reorganization constriction, formation conversion cuboidal columnar shapes spindle-like elongated forms (Moreno-Bueno 2008). Newly formed actin-rich protrusions lamellipodia filopodia movement. To surrounding tissues, induce invadopodia, specialized proteolytic function (Yilmaz Christofori, Eckert 2011; Ridley, Sundararajan 2015). supported induction matrix metalloproteases degradation adjacent tissues (Miyoshi 2004; Miyoshi 2005; Huang 2009) inducers prevent synthesis repressing its (Spaderna events cause loss integrity dissemination thus execute first step cascade 1A). MET: colonization 1990, Fearon Vogelstein proposed meanwhile genetic model colorectal tumorigenesis. described deterioration greater malignancy driven stepwise accumulation hypothesized perpetuates during last established malignant carcinoma metastases, implying metastases most degenerated (Fearon Vogelstein, 1990). efforts identify specific metastasis-associated remained unsuccessful. Rather, already twenty years ago, compared de-differentiated nature primary tumor, exhibit re-differentiated morphology, similar center These led hypothesis de-differentiation transient condition opposing re-differentiation needs initiated advantageous macrometastases (Figs 1A But why do re-differentiate? Invasive, were growth arrested, whereas proliferation detected metastasis, suggesting must reversed order fact inhibit 3). There publications confirming relevance (Chaffer 2006; Korpal Ocana 2012; Tsai perfect accordance failure EMT-causing attributed epigenetic regulation 3. Cellular plasticity governed provided window phenotypes cells. Drug sensitivity, proliferation, response apoptosis highest states, drug efflux, invasion, states. A hybrid provides maximal capacity, changes. Note extreme initiation, lost. Whereas investigated great detail below), less known about trigger reverse Is just lack EMT-inducing stimuli coupled reduced EMT-TFs? Several studies could show knockdown EMT-TF sufficient elicit vitro lines entities depletion Zeb1 mouse pancreatic fixes (Krebs Once ZEB-family (ZEB1 ZEB2) declines, reduction reinforced loop family microRNAs. During ZEB transcriptionally members. Vice versa, post-transcriptional level Thus, bidirectional transitions potentiated ZEB/miR-200 circuit (Bracken Burk Wellner 2009). branch inducible tumor-suppressor p53, miR-200s (Kim 2011). Upregulation consequences. It exerts both invasion- migration-inhibiting, tumor-suppressing (Peter, 2009), promotes (Korpal controversial, EMT-MET adapting respective Similar negative loop, miR-34 regulatory (Siemens Diaz-Lopez target themselves, BMI1, CD44, CD133, JAG1, MYC tumor-relevant "non-classical" discussed below Brabletz, 2010; Since slow multistep take requires different, sometimes apparently spatiotemporal manner, valid investigation remains challenging rely models. Recently, focusing EMT/MET using elegant 2012, al (2012) demonstrated induction, case TWIST, supports skin subsequent Twist1 downregulation necessary (Tsai 2012) Another study necessity MMTV-PyMT breast disseminate lung. EMT-state niche local fibroblasts turn (MET) (del Pozo Martin Esposito colleagues found E-selectin adhesion bone vascular elicits (Esposito summary, reports significance detailed still need further investigation. Partial long viewed binary separate populations. past, narrow perspective challenged means metastasis. One example analysis Fischer Fsp1-Cre lineage tracing Based finding lung consist had never switched full Fsp1+ authors concluded (Fischer nowadays accepted that, although reactivated types, fully end-stage Vimentin often expressed. rather gradual incomplete, termed Pastushenko Blanpain, 2019; Yang 2020) Over years, report vivo detection carrying combination markers. Already 1990s, analyses reported observations (Mareel 1992; Birchmeier Behrens, 1994). Later, circulating (CTCs) simultaneous (Yu 2013). Similarly, identified co-expression (EpCAM+) (Vim+) marker autochthonous murine prostate (Ruscetti linked single-cell transcriptomics head neck (Puram group occurring introduced term "hybrid" (Pastushenko 2018; 2021) Moreover, Bornes used (2015) incapable detecting majority disseminating partial/hybrid 2015; does mean important. evidence traps profoundly suppresses mammary (Ye oncogene-induced model, Xu (2017) required small subset (Xu Interestingly, modes involve levels observed. groups forming clusters. Indeed, type "collective migration" might common than dissemination, approaches clustered circulation (Friedl Aceto 2014; Cheung Nevertheless, despite appearance, characteristic detectable migrating (Aiello 2018), follow "leader" pave "follower" (Matise Chen Non-classical Besides drive phenotypes, regulating tumorigenesis Regulation Normal dependent source replenish dying committed terminally differentiated tissue. observation maintained after transplantations into mice, prompted (Reya Simplified, measured capability fractions mice. Strikingly, capacity increasing Shibue 2017; Wilson Overexpression SNAI1, TWIST1, CD44+/CD24lo pool, increased sphere vitro, elevated tumorigenicity (Mani Morel determines healthy gland converts luminal settings (Guo results obtained key determinant reciprocal ZEB1/miR-200 controlling BMI1 SOX2 (Shimono Krebs squamous (SCC) cooperatively CDKN2A (p16INK4A) promote capacities 2010). protocadherin FAT1 one player stemness. inactivated SCC involving CAMK2, SRC activities nuclear translocation YAP1 2021). another promoting factor, PRRX1, thereby uncoupling EMT/migration (Ocana PRRX1 isoform switching driving force (Takano Mechanistically, realm correlate gradually efficiencies seeding line idea addition (Shibue 2013; 2020), transformation. upregulation RAS transformed bronchial unleash favoring aggressive undifferentiated (Morel Liu 2014b; Larsen KRAS dependency (KRAS addiction) thresholds KRAS-dependent (Singh 2014b). effects evident ectopic Zeb2 intestinal epithelium transgenic Elevation generates absence cooperating defects (Slowicka 2020). Therapy Loss durable efficacy relapse initial successful treatment obstacles battle against Conventional favorably eliminating non-stem cell-like fails deplete properties. Settleman, Santamaria Dudas signatures acquisition strongly correlated, standard targeted EGFR PI3K inhibitors (Creighton Farmer Byers For example, gemcitabine-resistant Panc1 sensitized upon (Wellner routes include efflux evading anoikis former ATP-binding cassette (ABC) transporter family, FOXC1 (Aller Singh Saxena contribute therapy-induced interfering p53 PTEN, BCL-XL (Vega Escriva Kurrey Wu Cao Experimentally HMLER 10-fold IC50 doses chemotherapeutics (Gupta Tulchinsky experiments, GFP-labeled PyMT high cyclophosphamide non-small-cell (NSCLC), AXL receptor tyrosine kinase inhibition, sustained activity Sequist Zhang Furthermore, HDAC class I demethylation resensitizes osteosarcoma chemotherapy (Meidhof

Language: Английский

Citations

503

Emerging role of exosomes in cancer progression and tumor microenvironment remodeling DOI Creative Commons
Mahshid Deldar Abad Paskeh, Maliheh Entezari, Sepideh Mirzaei

et al.

Journal of Hematology & Oncology, Journal Year: 2022, Volume and Issue: 15(1)

Published: June 28, 2022

Abstract Cancer is one of the leading causes death worldwide, and factors responsible for its progression need to be elucidated. Exosomes are structures with an average size 100 nm that can transport proteins, lipids, nucleic acids. This review focuses on role exosomes in cancer therapy. We discuss how able modulate components tumor microenvironment influence proliferation migration rates cells. also highlight that, depending their cargo, suppress or promote cell enhance reduce response radio- chemo-therapies. In addition, we describe trigger chronic inflammation lead immune evasion by focusing ability transfer non-coding RNAs between cells other molecular signaling pathways such as PTEN PI3K/Akt cancer. Subsequently, use carriers anti-tumor agents genetic tools control progression. then tumor-derived carcinogenesis. Finally, devote a section study diagnostic prognostic clinical courses important treatment patients. provides comprehensive understanding therapy, therapeutic value remodeling microenvironment. Graphical

Language: Английский

Citations

362

Radiotherapy combined with immunotherapy: the dawn of cancer treatment DOI Creative Commons

Zengfu Zhang,

Xu Liu,

Dawei Chen

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: July 29, 2022

Abstract Radiotherapy (RT) is delivered for purposes of local control, but can also exert systemic effect on remote and non-irradiated tumor deposits, which called abscopal effect. The view RT as a simple treatment has dramatically changed in recent years, it now widely accepted that provoke immune response gives strong rationale the combination immunotherapy (iRT). Nevertheless, several points remain to be addressed such interaction system, identification best schedules with (IO), expansion mechanism amplify iRT. To answer these crucial questions, we roundly summarize underlying showing whole landscape clinical trials attempt identify In consideration rarity effect, propose occurrence induced by radiation promoted 100% molecular genetic level. Furthermore, “radscopal effect” refers using low-dose reprogram microenvironment may overcome resistance Taken together, could regarded trigger antitumor response, help IO used radical added into current standard regimen patients metastatic cancer.

Language: Английский

Citations

351

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status DOI Creative Commons
Gürcan Günaydın, Mustafa Emre Gedik, Seylan Ayan

et al.

Frontiers in Chemistry, Journal Year: 2021, Volume and Issue: 9

Published: Aug. 2, 2021

Photodynamic therapy (PDT) has been used as an anti-tumor treatment method for a long time and photosensitizers (PS) can be in various types of tumors. Originally, light is effective tool that the diseases ages. The effects combination specific dyes with illumination was demonstrated at beginning 20th century novel PDT approaches have developed ever since. Main strategies current studies are to reduce off-target improve pharmacokinetic properties. Given high interest vast literature about topic, approval first drug/device by FDA should come no surprise. consists two stages treatment, combining energy PS order destruct tumor cells after activation light. In general, fewer side toxicity than chemotherapy and/or radiotherapy. addition purpose several PSs diagnostic purposes Such called photodynamic diagnosis (PDD). this Review, we provide general overview clinical applications cancer, including therapeutic approaches. Assessment efficacy clinic will discussed, since identifying predictors determine response crucial. addition, examples tumors discussed. Furthermore, other modalities such chemotherapy, radiotherapy, surgery immunotherapy emphasized, seem promising terms enhancing effectiveness against tumor. treatments may yield better results single treatments. Moreover, utilization lower doses setting cause less therapy. A understanding well optimization complex multimodal expand PDT.

Language: Английский

Citations

294

Statins: a repurposed drug to fight cancer DOI Creative Commons
Wen Jiang,

Jin-Wei Hu,

Xu-Ran He

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2021, Volume and Issue: 40(1)

Published: July 24, 2021

As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties have attracted much attention indicated potential as repurposed drugs for treatment cancer. A large number clinical epidemiological studies described anticancer statins, evidence effectiveness is inconsistent. It may be certain molecular subtypes cancer more vulnerable to statin therapy than others. Whether still an active area research. Statins appear enhance efficacy address shortcomings associated with conventional treatments, suggesting should considered in context combined therapies Here, we present a comprehensive review treatments. We discuss current understanding mechanisms underlying on different malignancies. provide recommendations design future well-designed trials statins.

Language: Английский

Citations

260

Anticancer drug resistance: An update and perspective DOI Creative Commons
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang

et al.

Drug Resistance Updates, Journal Year: 2021, Volume and Issue: 59, P. 100796 - 100796

Published: Dec. 1, 2021

Driver mutations promote initiation and progression of cancer. Pharmacological treatment can inhibit the action mutant protein; however, drug resistance almost invariably emerges. Multiple studies revealed that cancer is based upon a plethora distinct mechanisms. Drug occur in same protein or different proteins; as well pathway parallel pathways, bypassing intercepted signaling. The dilemma clinical oncologist facing not all genomic alterations tumor microenvironment facilitate cell proliferation are known, neither likely to metastasis. For example, common KRas

Language: Английский

Citations

248

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant DOI Creative Commons
Chang Yang, Bairong Xia,

Zhao-Cong Zhang

et al.

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: Oct. 6, 2020

Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are primary treatments for ovarian cancer; however, patients often succumb to recurrence with chemotherapeutic resistance within several years after initial treatment. In past two decades, immunotherapy has rapidly developed revolutionize treatment of various types cancer. Despite fact that response rates among remain modest, immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR)- TCR-engineered T cells developing. Therapeutic efficiency could be improved significantly if included as an adjuvant therapy, in combination chemotherapy, radiation anti-angiogenesis drugs, poly ADP ribose polymerase (PARPi). Newly technologies identify therapeutic targets, predict efficacy, screen potential provide neoadjuvant immunotherapy, utilize nanomedicine technology new opportunities have prolong patient survival. However, important issues may hinder efficacy such approaches, including hyperprogressive disease (HPD), immunotherapy-resistance, toxicity treatments, neurotoxicity, must taken into account addressed these therapies effective.

Language: Английский

Citations

241

Tumor microenvironment: barrier or opportunity towards effective cancer therapy DOI Creative Commons
Aadhya Tiwari, Rakesh Trivedi, Shiaw‐Yih Lin

et al.

Journal of Biomedical Science, Journal Year: 2022, Volume and Issue: 29(1)

Published: Oct. 17, 2022

Abstract Tumor microenvironment (TME) is a specialized ecosystem of host components, designed by tumor cells for successful development and metastasis tumor. With the advent 3D culture advanced bioinformatic methodologies, it now possible to study TME’s individual components their interplay at higher resolution. Deeper understanding immune cell’s diversity, stromal constituents, repertoire profiling, neoantigen prediction TMEs has provided opportunity explore spatial temporal regulation therapeutic interventions. The variation TME composition among patients plays an important role in determining responders non-responders towards cancer immunotherapy. Therefore, there could be possibility reprogramming overcome widely prevailing issue immunotherapeutic resistance. focus present review understand complexity comprehending future perspective its as potential targets. later part describes sophisticated models emerging valuable means extensive account tools profile predict neoantigens. Overall, this provides comprehensive current knowledge available target TME.

Language: Английский

Citations

208

B7-H3/CD276: An Emerging Cancer Immunotherapy DOI Creative Commons

Wu-Tong Zhou,

Weilin Jin

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: July 19, 2021

Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for therapy. B7 homolog 3 protein (B7-H3, also known as CD276), newly identified immunoregulatory member of family, is an attractive promising target immunotherapy because it overexpressed in tissues while showing limited expression normal participating microenvironment (TME) shaping development. Thus far, numerous B7-H3-based strategies have demonstrated potent antitumor activity acceptable safety profiles preclinical models. Herein, we present biological function B7-H3 distinct cells, well B7-H3-mediated signal pathways cells strategies. This review provides comprehensive overview that encompasses B7-H3’s role TME to its potential immunotherapy.

Language: Английский

Citations

198

Strategies for enhancing cancer chemodynamic therapy performance DOI
Deblin Jana,

Yanli Zhao

Exploration, Journal Year: 2022, Volume and Issue: 2(2)

Published: March 7, 2022

Chemodynamic therapy (CDT) has emerged to be a frontrunner amongst reactive oxygen species-based cancer treatment modalities. CDT utilizes endogenous H

Language: Английский

Citations

196